Vonicog alfa
As of the edition of 20 October 2026, Vonicog alfa is a protein: marketed, first approved in 2015 (US); US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Protein
- Brand name
- Vonvendi
- First approved
- 8 December 2015 (US)
- Approvals on record
- 8 in 4 regions
- Holder of the most recent approval
- Takeda; 3 holders in all
- Registered trials
- 8, 0 stopped early
- Disease areas
- Blood and lymph; Inherited and neonatal
US protection
US protection ends in 2032.
The orphan exclusivity ends in 2032 (it covers one use only). The application that gives this date is held by Takeda.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 1 | 0 |
| Phase 3 | 6 | 4 | 2 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Takeda | Applicant, Acquired holder, Earlier holder and Lead sponsor of trials | 2011 to now |